Evaluating the therapeutic effect and toxicity of theophylline in infertile men with asthenoteratozoospermia: a double-blind, randomized clinical trial study.

Abstract

Theophylline as a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor (cAMP-PDEI) elevates cAMP levels. We aimed to evaluate the therapeutic effect and toxicity of theophylline on the sperm parameters, oxidative stress (OS), and inflammation in asthenoteratozoospermic men. Sixty asthenoteratozoospermic patients were divided into groups of placebo and theophylline (200 mg/day). After 3 months of oral treatment, sperm parameters, viability, and DNA fragmentation were analyzed by the CASA system, eosin nigrosin staining, sperm DNA fragmentation kit, respectively. The seminal plasma level of reactive oxygen species (ROS) of neat semen samples, malondialdehyde (MDA), total antioxidant capacity (TAC), tumor necrosis factor alpha (TNF-α), and interleukin-10 (IL-10) was assessed. Data were analyzed statistically using the independent samples t-test and the paired t-test and the means were considered significantly different at p < 0.05. Sperm motility, viability, and the number of sperms with normal morphology and the seminal plasma level of TAC and IL-10 and also sperm DNA fragmentation increased significantly in the theophylline group compared to the placebo. The MDA, TNF-α, and ROS levels decreased significantly in the theophylline group compared to the placebo. Theophylline improved sperm parameters, reduced OS and inflammation, but also created genotoxicity and increased sperm DNA fragmentation. Therefore, to benefit from the desired effects of theophylline and inhibit the toxicity of it in the treatment of men with asthenoteratozoospermia, it is suggested to be used simultaneously with another antioxidant to protect sperm DNA from fragmentation.

• Authors: Atena Sadat Azimi, Malek Soleimani Mehranjani, Seyed Mohammad Ali Shariatzadeh, Alireza Noshad Kamran, Ali Asghar Ghafarizadeh
• Journal: Drug and chemical toxicology (Drug Chem Toxicol) Vol. 45 Issue 6 Pg. 2786-2793 (Nov 2022) ISSN: 1525-6014 [Electronic] United States
• PMID: 34696674 (Publication Type: Randomized Controlled Trial, Journal Article)

Chemical References

• Adenosine Monophosphate
• Antioxidants
• Eosine Yellowish-(YS)
• Interleukin-10
• Malondialdehyde
• Phosphodiesterase Inhibitors
• Reactive Oxygen Species
• Theophylline
• Tumor Necrosis Factor-alpha

Topics

• Humans
• Male
• Adenosine Monophosphate (metabolism, pharmacology)
• Antioxidants (adverse effects, metabolism)
• Asthenozoospermia (drug therapy, metabolism, pathology)
• DNA Fragmentation
• Eosine Yellowish-(YS) (metabolism, pharmacology)
• Infertility, Male (pathology)
• Inflammation (pathology)
• Interleukin-10 (genetics)
• Malondialdehyde (metabolism)
• Oxidative Stress
• Phosphodiesterase Inhibitors (metabolism, pharmacology)
• Reactive Oxygen Species (metabolism)
• Semen (metabolism)
• Sperm Motility
• Spermatozoa
• Theophylline (adverse effects, therapeutic use)
• Tumor Necrosis Factor-alpha (metabolism)